Literature DB >> 29030333

Genomics of Immunotherapy-Associated Hyperprogressors-Response.

Shumei Kato1, Razelle Kurzrock2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29030333     DOI： 10.1158/1078-0432.CCR-17-1990

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  6 in total

1.  Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden.

Authors:  Jan Budczies; Anja Seidel; Petros Christopoulos; Volker Endris; Matthias Kloor; Balázs Győrffy; Barbara Seliger; Peter Schirmacher; Albrecht Stenzinger; Carsten Denkert
Journal:  Oncoimmunology       Date:  2018-10-19       Impact factor: 8.110

Review 2.  Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review.

Authors:  Miaozhen Lin; Ben G L Vanneste; Qiwen Yu; Zebin Chen; Jiayu Peng; Xiuyu Cai
Journal:  Transl Lung Cancer Res       Date:  2021-07

3.  Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials.

Authors:  Yoon-Koo Kang; Martin Reck; Paul Nghiem; Yan Feng; Gregory Plautz; Hye Ryun Kim; Taofeek K Owonikoko; Narikazu Boku; Li-Tzong Chen; Ming Lei; Han Chang; Wen Hong Lin; Amit Roy; Akintunde Bello; Jennifer Sheng
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 13.751

Review 4.  Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?

Authors:  Mo-Xuan Wang; Shu-Yue Gao; Fan Yang; Run-Jia Fan; Qin-Na Yang; Tian-Lan Zhang; Nian-Song Qian; Guang-Hai Dai
Journal:  World J Clin Oncol       Date:  2022-09-24

5.  Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors.

Authors:  Marjorie Faure; Philippe Rochigneux; Daniel Olive; Sébastien Taix; Isabelle Brenot-Rossi; Marine Gilabert
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

Review 6.  Hyperprogression Under Immune Checkpoint-Based Immunotherapy-Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model.

Authors:  Mikolaj Kocikowski; Katarzyna Dziubek; Maciej Parys
Journal:  Cancers (Basel)       Date:  2020-03-27       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.